CDE Launches CARE Plan to Streamline Rare Disease Drug Development
The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...
NMPA
South Korea’s MFDS Aims to Slash Drug Approval Times with New Innovation Plan
South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled an ambitious plan to...
China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...
China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion
China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...
NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of...
China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns
BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...
NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns
BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...
China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety
BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...
China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management
The National Medical Products Administration (NMPA) of China has issued a new set of regulations...
China’s CDE Seeks Public Comment on Latest Generic Drug Reference Preparations
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) is currently...
China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals
The National Medical Products Administration (NMPA) of China has given the green light to Beijing...
China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs
In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...
China Expands Controlled Substances Catalogue to Include Three Additional Substances
The Ministry of Public Security, National Health Commission, and National Medical Products Administration in China...
NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...
China’s NMPA Unveils Three-Year Smart Supervision Plan for Blood Product Industry
China’s National Medical Products Administration (NMPA) has unveiled the “Three-Year Action Plan for Smart Supervision...
China’s NMPA Issues New Supervision Measures for Medical Device Clinical Trials Starting October 2024
The National Medical Products Administration (NMPA) has approved the “Measures for Supervision and Inspection of...
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate...
NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...
China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023
The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...